Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population

30 August 2024 (12:00 - 12:50)

Organised by:

Video

Abstract

Sign in to view the resources

Slides

About the speaker

Professor Maria Generosa Crespo-Leiro

CHUAC, A Coruna (Spain)

8 More presentations in this session

Presentation thumbnail

Effects of Sacubitril/Valsartan on all-cause hospitalizations in heart failure: participant-level pooled analysis of PARADIGM-HF and PARAGON-HF

Doctor H. Lu (Lausanne, CH)

Abstract Slides Video

Presentation thumbnail

Efficacy of sotagliflozin by diabetes duration: a secondary analysis of SCORED

Doctor R. Aggarwal (Boston, US)

Abstract Slides Video

Presentation thumbnail

Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER

Doctor J. Butt (Copenhagen, DK)

Abstract Slides Video

Presentation thumbnail

Long-term follow-up of the TRED-HF trial

Miss L. Cheng (London, GB)

Abstract Slides Video

Presentation thumbnail

Utilization and safety of digoxin in patients with chronic heart failure and atrial fibrillation with rapid ventricular rate

Doctor K. Berge (Nordbyhagen, NO)

Abstract Slides Video

Access the full session

Session thumbnail

Drug therapy for heart failure: what is new?

The Event

Event poster

ESC Congress 2024

30 August 2024 12:00 CET

You may be interested in

Congress Presentation

Outcomes with early access tafamidis in patients with variant transthyretin amyloid cardiomyopathy

Congress Session

Advances in amyloidosis

Congress Presentation

Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources